Article
Oncology
Tomiyuki Sugi, Yasuo Nishigami, Hirohisa Saigo, Homare Hanai, Keisuke Takabatake, Mitsuo Mita, Shin Ohara, Shiro Ide, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara
Summary: Advanced age, BJP-subtype of myeloma, and no prior chemotherapy were identified as significant risk factors for Len-associated skin rash based on the retrospective investigation of 144 multiple myeloma patients treated with Len-containing therapies. It is suggested that patients with these risk factors should be closely monitored for the appearance of skin rash during Len treatment.
LEUKEMIA & LYMPHOMA
(2021)
Article
Pharmacology & Pharmacy
Tomiyuki Sugi, Mitsuo Mita, Takeo Yasu, Shin Ohara, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara
Summary: This study presents 5 cases of severe LEN-induced skin rash treated with a simple, slow desensitization protocol, with all patients successfully re-administered LEN without adverse reactions. The findings suggest that this desensitization protocol is effective in desensitizing patients without reducing the effectiveness of LEN, especially recommended for elderly patients without assistance from family members.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Jesus San-Miguel, Binod Dhakal, Kwee Yong, Andrew Spencer, Sebastien Anguille, Maria-Victoria Mateos, Carlos Fernandez de Larrea, Joaquin Martinez-Lopez, Philippe Moreau, Cyrille Touzeau, Xavier Leleu, Irit Avivi, Michele Cavo, Tadao Ishida, Seok Jin Kim, Wilfried Roeloffzen, Niels W. C. J. van de Donk, Dominik Dytfeld, Surbhi Sidana, Luciano J. Costa, Albert Oriol, Rakesh Popat, Abdullah M. Khan, Yael C. Cohen, P. Joy Ho, James Griffin, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan M. Schecter, Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, T. Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele
Summary: In patients with lenalidomide-refractory multiple myeloma, Ciltacabtagene autoleucel (CAR-T cell therapy) showed a lower risk of disease progression or death compared to standard care, highlighting its effectiveness in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Biotechnology & Applied Microbiology
Li Du, Wei Liu, Flavia Pichiorri, Steven T. Rosen
Summary: This study identified SUMOylation as a potential mechanism regulating lenalidomide resistance in multiple myeloma. Inhibition of SUMOylation can enhance sensitivity to lenalidomide by downregulating IRF4 expression.
CANCER GENE THERAPY
(2023)
Review
Oncology
Felipe de Arriba de la Fuente, Carmen Montes Gaisan, Javier de la Rubia Comos
Summary: Lenalidomide is a key drug for the treatment of multiple myeloma, but excessive use has led to treatment resistance. This review summarizes the current treatment options and discusses potential future therapies. While lenalidomide-based combinations can improve the response rate and survival of multiple myeloma patients, the strategy of using them as a frontline treatment has resulted in early development of resistance. Therefore, there is a need for other treatment options.
Article
Biochemistry & Molecular Biology
Alessandra Romano, Nunziatina Laura Parrinello, Marina Parisi, Vittorio Del Fabro, Angelo Curtopelle, Salvatore Leotta, Concetta Conticello, Francesco Di Raimondo
Summary: The study investigated the functional activity of neutrophils in RRMM patients treated with pomalidomide and dexamethasone. The results showed compromised neutrophil function but maintained high blood cell counts. Pomalidomide and lenalidomide were found to modulate the functional activity of neutrophils, despite chronic activation due to Fc gamma RI/CD64 overexpression.
Article
Hematology
Sarah Gooding, Naser Ansari-Pour, Fadi Towfic, Maria Ortiz Estevez, Philip P. Chamberlain, Kao-Tai Tsai, Erin Flynt, Marissa Hirst, Dan Rozelle, Paula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas, Anjan Thakurta
Summary: The study found that in patients with myeloma, as the exposure to IMiD drugs increased, the frequency of CRBN abnormalities also increased gradually, with almost one-third of patients having CRBN alterations by the time they were refractory to pomalidomide (POM). These CRBN abnormalities were associated with inferior outcomes to POM in patients already refractory to lenalidomide (LEN).
Review
Hematology
Georgia J. McCaughan, Sara Gandolfi, John J. Moore, Paul G. Richardson
Summary: For patients with newly diagnosed multiple myeloma, optimizing induction therapy is crucial for long-term disease control. The current standard of care involves the combination of lenalidomide and bortezomib with dexamethasone (RVD) as induction treatment, followed by maintenance until disease progression.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Daniele Caracciolo, Caterina Riillo, Giada Juli, Francesca Scionti, Katia Todoerti, Nicoletta Polera, Katia Grillone, Lucia Fiorillo, Mariamena Arbitrio, Maria Teresa Di Martino, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone
Summary: The MYC-driven deregulation of microRNAs, particularly the repression of miR-22, plays a critical role in multiple myeloma (MM) and resistance to immunomodulatory imide drugs (IMiDs). Lenalidomide treatment enhances miR-22 activity by reducing MYC inhibition, which restores drug sensitivity and leads to synergistic anti-MM activity.
Review
Biochemistry & Molecular Biology
Maria Gavriatopoulou, Stavroula A. Paschou, Ioannis Ntanasis-Stathopoulos, Meletios A. Dimopoulos
Summary: Multiple myeloma is characterized by monoclonal proliferation of plasma cells in the bone marrow and cancer cells deregulate metabolic pathways to ensure their proliferation, survival, and avoid immune surveillance. Metabolic syndrome, inflammatory cytokines, and the use of metformin and statins have been associated with the incidence and prognosis of MM. Targeting dysregulated pathways in MM may enhance antitumor therapeutics.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Yuen Lam Dora Ng, Evelyn Ramberger, Stephan R. Bohl, Anna Dolnik, Christian Steinebach, Theresia Conrad, Sina Mueller, Oliver Popp, Miriam Kull, Mohamed Haji, Michael Guetschow, Hartmut Doehner, Wolfgang Walther, Ulrich Keller, Lars Bullinger, Philipp Mertins, Jan Kroenke
Summary: The study identifies CDK6 upregulation as a druggable target in IMiD-resistant multiple myeloma through integrated proteomic, phosphoproteomic, and RNA sequencing analysis.
NATURE COMMUNICATIONS
(2022)
Article
Hematology
Jacob Stroh, Anja Seckinger, Michael Heider, Martina Rudelius, Ruth Eichner, Markus Schick, Jolanta Slawska, Martina Emde-Rajaratnam, Hans Salwender, Uta Bertsch, Hartmut Goldschmidt, Katja Weisel, Christof Scheid, Ulrich Keller, Dirk Hose, Florian Bassermann
Summary: In this study, researchers found that MCT1 expression levels were correlated with the survival of patients with multiple myeloma (MM) receiving lenalidomide maintenance therapy. High expression levels of MCT1 were associated with shorter progression-free survival (PFS) and overall survival (OS) in cases with lenalidomide maintenance. However, MCT1 expression did not significantly impact PFS or OS in cases with bortezomib maintenance. These findings suggest that MCT1 can serve as a predictive marker for response to lenalidomide-based maintenance therapy in MM patients.
Article
Hematology
Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. Kumar, Paul G. Richardson, S. Vincent Rajkumar
Summary: Continuous treatment with lenalidomide-dexamethasone (Rd) plus ixazomib showed a progression-free survival benefit compared to placebo in transplant-ineligible newly diagnosed multiple myeloma patients. Addition of ixazomib to Rd led to higher rates of complete and very good partial response, especially in high-risk cytogenetics subgroup. The combination therapy was generally well-tolerated with manageable toxicities and no new safety signals observed.
Article
Oncology
Phyllis S. Y. Chong, Jing-Yuan Chooi, Julia S. L. Lim, Aaron C. Y. Leow, Sabrina Hui Min Toh, Irfan Azaman, Mun Yee Koh, Phaik Ju Teoh, Tuan Zea Tan, Tae-Hoon Chung, Wee Joo Chng
Summary: Aberrant glycolysis driven by NSD2-mediated upregulation of PKC alpha can be targeted therapeutically using metabolic inhibitors. Lactate can serve as a biomarker to identify high-risk patients with poor response to IMiD-based regimens.
Letter
Dermatology
Solomiya Grushchak, Regine J. Mathieu, Kelsey A. Orrell, Erika L. Hagstrom, Anne E. Laumann, Dennis P. West, Beatrice Nardone
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2018)
Letter
Dermatology
Kelsey A. Orrell, Alfred W. Rademaker, Dennis P. West, Beatrice Nardone
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2019)
Letter
Dermatology
Supriya Rastogi, Kevin R. Patel, Vivek Singam, Yasmeen Ali, Jing Gao, Ahmad Amin, Bethanee J. Schlosser, Dennis P. West, Beatrice Nardone
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2019)
Letter
Dermatology
Ryan C. Kelm, Erika L. Hagstrom, Regine J. Mathieu, Kelsey A. Orrell, Linda Serrano, Kelly A. Mueller, Anne E. Laumann, Dennis P. West, Beatrice Nardone
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2019)
Letter
Dermatology
K. A. Orrell, R. C. Kelm, M. Murphrey, S. Nagiredla, B. Wu, H. Abu-Zayed, B. J. Schlosser, D. P. West, B. Nardone
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2019)
Article
Dermatology
Sara Majewski, Tanya Bhattacharya, Manuela Asztalos, Benjamin Bohaty, Katherine C. Durham, Dennis P. West, Adelaide A. Hebert, Amy S. Paller
PEDIATRIC DERMATOLOGY
(2019)
Letter
Dermatology
C. Kosche, A. Para, J. Brieva, D. P. West, F. J. Palella, B. Nardone
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2019)
Letter
Dermatology
D. R. Pease, M. E. Martinez-Escala, J. Jimenez, J. Guitart, D. P. West, B. Nardone
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Review
Dermatology
Amr Ehab El-Qushayri, Mariam Abdelmageed Mahmoud, Samar Salman, Sameh Sarsik, Beatrice Nardone
Summary: This meta-analysis aimed to evaluate the safety of dupilumab use in managing atopic dermatitis (AD) during the COVID-19 pandemic. The results showed a low prevalence of COVID-19 in AD patients treated with dupilumab, with most cases having mild symptoms and no severe or fatal cases. Therefore, the continuation of dupilumab in AD patients is safe and beneficial for disease outcomes.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Amr Ehab El-Qushayri, Beatrice Nardone
Summary: Recent reports have shown worsening skin conditions in patients with psoriasis after receiving COVID-19 vaccines. This study analyzed data from 51 patients and found that psoriasis exacerbation was more common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines.
DERMATOLOGIC THERAPY
(2022)
Review
Health Care Sciences & Services
Kelly A. Reynolds, Vishnu B. Harikumar, Emily Poon, Dennis P. West, Murad Alam
Summary: This study aimed to determine the common reasons for deferral of biomedical research proposals by Institutional Review Boards (IRBs). The results showed that ethical considerations were more likely than scientific merit to be a reason for protocol deferral. Common ethical considerations included inadequate informed consent, insufficient detail for risk assessment, inadequate protection of participant safety, and inadequate minimization of risks. Additionally, non-sponsored, investigator-initiated proposals were more likely to be deferred, often due to inadequate protocol development, lack of external vetting and oversight, and submissions from inexperienced faculty.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2022)
Letter
Dermatology
Giuseppe Micali, Anna Elisa Verzi, Maria Letizia Musumeci, Beatrice Nardone, Giuseppe Monfrecola, Francesco Lacarrubba
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Meeting Abstract
Dermatology
Rebecca Thiede, Yasmeen Ali, Gene Schwartz, Kara Ramsey, Beatrice Nardone, Dennis West
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2018)
Meeting Abstract
Dermatology
Paras Vakharia, Rame Yousif, Kevin Patel, Stephanie Rangel, Dennis West, Beatrice Nardone
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2018)
Letter
Dermatology
B. Nardone, D. P. West
BRITISH JOURNAL OF DERMATOLOGY
(2018)
